CeriBell (NASDAQ:CBLL) VP Sells $11,260.51 in Stock

CeriBell, Inc. (NASDAQ:CBLL) VP David Foehr sold 569 shares of the company’s stock in a transaction on Monday, February 23rd. The stock was sold at an average price of $19.79, for a total value of $11,260.51. Following the transaction, the vice president owned 18,331 shares in the company, valued at $362,770.49. This trade represents a 3.01% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.

David Foehr also recently made the following trade(s):

• On Tuesday, February 24th, David Foehr sold 781 shares of CeriBell stock. The shares were sold at an average price of $19.98, for a total value of $15,604.38.
• On Tuesday, February 3rd, David Foehr sold 5,556 shares of CeriBell stock. The stock was sold at an average price of $20.00, for a total value of $111,120.00.
• On Monday, January 5th, David Foehr sold 5,556 shares of CeriBell stock. The shares were sold at an average price of $22.60, for a total value of $125,565.60.
• On Wednesday, December 3rd, David Foehr sold 5,265 shares of CeriBell stock. The shares were sold at an average price of $16.83, for a total transaction of $88,609.95.

CeriBell Price Performance

CeriBell stock opened at $18.67 on Friday. The company has a quick ratio of 12.25, a current ratio of 9.73 and a debt-to-equity ratio of 0.13. CeriBell, Inc. has a 52-week low of $10.01 and a 52-week high of $24.68. The firm has a market cap of $702.74 million, a PE ratio of -12.70 and a beta of 1.03. The company’s 50 day moving average is $21.11 and its two-hundred day moving average is $16.26.

CeriBell (NASDAQ:CBLL) last posted its quarterly earnings results on Tuesday, February 24th. The company reported ($0.36) EPS for the quarter, topping the consensus estimate of ($0.43) by $0.07. The business had revenue of $24.78 million during the quarter, compared to the consensus estimate of $23.95 million. CeriBell had a negative net margin of 59.97% and a negative return on equity of 31.77%. On average, research analysts expect that CeriBell, Inc. will post -2.46 EPS for the current fiscal year.

Institutional Trading of CeriBell

A number of hedge funds and other institutional investors have recently made changes to their positions in CBLL. Russell Investments Group Ltd. boosted its position in shares of CeriBell by 41.4% in the 4th quarter. Russell Investments Group Ltd. now owns 2,918 shares of the company’s stock valued at $64,000 after purchasing an additional 854 shares during the period. Caitong International Asset Management Co. Ltd boosted its holdings in shares of CeriBell by 3,971.0% in the fourth quarter. Caitong International Asset Management Co. Ltd now owns 1,262 shares of the company’s stock valued at $28,000 after acquiring an additional 1,231 shares during the period. Ameritas Investment Partners Inc. increased its holdings in shares of CeriBell by 97.5% in the 2nd quarter. Ameritas Investment Partners Inc. now owns 2,544 shares of the company’s stock valued at $48,000 after acquiring an additional 1,256 shares during the period. Deutsche Bank AG raised its position in CeriBell by 1.7% in the 4th quarter. Deutsche Bank AG now owns 85,182 shares of the company’s stock valued at $1,868,000 after purchasing an additional 1,393 shares during the last quarter. Finally, Royal Bank of Canada boosted its stake in CeriBell by 10.8% during the 4th quarter. Royal Bank of Canada now owns 15,588 shares of the company’s stock worth $342,000 after purchasing an additional 1,514 shares during the period.

Wall Street Analysts Forecast Growth

Several equities analysts have recently issued reports on CBLL shares. TD Cowen reiterated a “buy” rating on shares of CeriBell in a research note on Tuesday, December 9th. Canaccord Genuity Group lifted their price target on shares of CeriBell from $29.00 to $30.00 and gave the stock a “buy” rating in a research note on Wednesday, December 17th. BTIG Research reaffirmed a “buy” rating and set a $30.00 price objective on shares of CeriBell in a research report on Wednesday, January 28th. Finally, JPMorgan Chase & Co. dropped their target price on CeriBell from $21.00 to $17.00 and set an “overweight” rating on the stock in a report on Wednesday, November 5th. One research analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, CeriBell currently has a consensus rating of “Moderate Buy” and a consensus target price of $24.67.

About CeriBell

CeriBell Corp (NASDAQ: CBLL) is a healthcare technology company specializing in the design, manufacture and sale of automated newborn hearing screening devices. The company offers a suite of medical diagnostic tools based on otoacoustic emissions (OAE) and auditory brainstem response (ABR) technologies, enabling early detection of auditory impairments in infants. CeriBell’s solutions are used in hospitals, birthing centers and audiology clinics to support universal newborn hearing screening programs aimed at improving language development outcomes through prompt intervention.

The company’s product portfolio includes handheld and desktop screening units, proprietary software for data management, and accessories designed to streamline testing workflows.